Halozyme Therapeutics reported a 48% year-over-year revenue increase in Q2 2026, driven by a 50% rise in royalty revenue and EBITDA margins reaching 68%. The company is transitioning from dependence on a single product, DARZALEX SC, to a broader, high-margin royalty platform with multiple mature and new product streams. This diversification, along with a robust pipeline targeting launches from 2029 onward, supports the company's raised full-year guidance across key metrics. Despite strong growth and expanding deals, Halozyme's stock trades at discounted earnings multiples, making it an attractive buy for investors seeking long-term growth potential.
Energy Fuels CEO Bhappu sold 14,375 shares of the company to cover tax withholding obligations. This transaction is a routine financial move related to tax compliance and does not indicate a change in company leadership or strategy. Investors should ...
Shares of Fresnillo and Endeavour Mining fell as gold prices dropped to their lowest in nearly two weeks, influenced by expectations of further US interest rate hikes after Federal Reserve warnings. Fresnillo fell 3% initially but later recovered sli...
The GRAM token increased about 2% to $1.40 following Telegram's initial distribution of its Gram Wallet to select users, sparking a 137% surge in trading volume. The Gram Wallet is a self-custodial, fee-free wallet integrated within Telegram, allowin...
In Q2 2026, Ripple Labs became the largest private company holding in the NYSE-listed C1 Fund's portfolio, representing 17.5% of its net assets, surpassing Kraken's parent company Payward at 16.9%. The fund's Ripple shares generated a 150% return fro...
Upstart Holdings is positioned as a resilient AI-powered lending platform with growing fee-based revenues and third-party funding capacity. The company is expected to expand margins further from fiscal year 2027, driven by robust unsecured loan growt...
